Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizophrenia: full-pipeline trial registry
76 of 318 indexed Schizophrenia trials are currently recruiting.
Corpus placement: #23 of 28,707 conditions by registered trial count.
318 US clinical trials · 76 currently recruiting · #23 of 28,707 conditions by registered trial count
Schizophrenia: 318 US clinical trials tracked, 76 recruiting.
Schizophrenia is the subject of 318 registered US clinical trials on ClinicalTrials.gov, 76 of them currently open to new participants. 90 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 14 of these trials.
Enrollment posture brief
Registry condition schizophrenia
OPEN 76 | RECR 24% | LATE 90 | EARLY 87 | RANK #23 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Dehydration (24% recruiting · 21 trials)
Schizophrenia lists 76 open slots (24% of 318 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizophrenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizophrenia is recruiting below its size-band peers.
76 of 318 indexed trials (23.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizophrenia trials is spread across many organizations.
University of Maryland, Baltimore accounts for 14 of 318 trials (4.4%). 129 distinct sponsors appear on at least one study for this condition label.
-
Typical Schizophrenia enrolment sits around 83 participants.
Median target enrolment is 83 among the 316 trials that report a genuine target (sentinel values excluded). 169 of those (53.5%) plan for fewer than 100 participants.
-
Schizophrenia research is mostly interventional.
290 interventional and 28 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
318 total, page 2 of 7
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Louisiana State University Health Sciences Center Shreveport
NCT06482554
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
Fabio Ferrarelli
NCT05102929
Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study
Rutgers, The State University of New Jersey
NCT06745479
Cognitive Training for Emotion Regulation in Psychotic Disorders
University of Georgia
NCT04414215
Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia
Mclean Hospital
NCT05343598
The Effects of Auditory Stimulation During Sleep on Brain Networks in Schizophrenia
Massachusetts General Hospital
NCT06386588
Imaging Synapses With [11C] UCB-J in the Human Brain
Davidzon, Guido, M.D.
NCT04038840
Prebiotic Treatment in People With Schizophrenia
University of Maryland, Baltimore
NCT05527210
A Study to Evaluate the Effect of KarXT on Urological Safety
Bristol-Myers Squibb
NCT07221877
Acetazolamide for Treatment Resistant Schizophrenia
Vishwajit Nimgaonkar, MD PhD
NCT04887792
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
Temple University
NCT06336616
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
University of Massachusetts, Worcester
NCT06174116
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
NCT07105111
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
The University of Texas Health Science Center, Houston
NCT05276050
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
Bristol-Myers Squibb
NCT07061288
Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Northwell Health
NCT05389787
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
University of California, Los Angeles
NCT05778591
Deep rTMS Modulating Insula Synaptic Density and Smoking Behavior in Schizophrenia
Stony Brook University
NCT05724810
TMS for Inhibition Enhancement in Schizophrenia
University of Maryland, Baltimore
NCT06155682
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
Deepak K. Sarpal, M.D.
NCT06003036
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
University of Arizona
NCT03781115
Tolerability of MDMA in Schizophrenia
Anya Bershad, MD, PhD
NCT05770375
Anti-Inflammatory Challenge in Schizophrenia
Emory University
NCT05823532
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
Nicholas Breitborde
NCT04368039
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
VA Office of Research and Development
NCT05491538
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Corporal Michael J. Crescenz VA Medical Center
NCT03495024
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
National Institute of Mental Health (NIMH)
NCT00001246
Database Registry for Neural Network Biomarkers in Psychosis
University of Texas Southwestern Medical Center
NCT01409109
ERG Components in Schizophrenia and Bipolar Disorder Type I
diaMentis
NCT03788811
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
Boehringer Ingelheim
NCT06791122
EPI-MINN: Targeting Cognition and Motivation - National
University of Minnesota
NCT05877716
Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
University of Texas Southwestern Medical Center
NCT04951700
A Study of ANAVEX3-71 in Adults With Schizophrenia
Anavex Life Sciences
NCT06245213
Effects of Auditory Stimulation on Sleep and Memory in Schizophrenia
Massachusetts General Hospital
NCT04783571
Ketogenic Diet in People With Schizophrenia
University of Maryland, Baltimore
NCT05968638
Optimizing CBSST With Executive Function Training for Schizophrenia
University of California, San Diego
NCT06251193
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Washington University School of Medicine
NCT05838560
Treating Schizophrenia by Correcting Abnormal Brain Development
Beth Israel Deaconess Medical Center
NCT00179465
Study of SPG302 in Adults With Schizophrenia
Spinogenix
NCT06442462
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
BioXcel Therapeutics
NCT07116694
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
Yale University
NCT02102113
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
Columbia University
NCT05756855
Genetic Study of Schizophrenia
National Institute of Mental Health (NIMH)
NCT00001486
Person-Centered Versus Measurement-Based Care in Mental Health
University of Pittsburgh
NCT02507349
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
Janssen Research & Development
NCT01515423
Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings
National Institute of Mental Health (NIMH)
NCT00001921
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization
NCT00731549
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
VA Office of Research and Development
NCT00137280
A Study in Schizophrenia Patients
Eli Lilly and Company
NCT01086748
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization
NCT00705783
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 40 |
| Phase 3 | 50 |
| Phase 4 | 40 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizophrenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizophrenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizophrenia page
318 registered trials, 76 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 76 Schizophrenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizophrenia trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizophrenia condition card totals 318 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.